Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy

References

• Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472–4478. doi: 10.1200/JCO.2006.05.6382
   PubMed Web of Science ®Google Scholar
• Tamura K, Aiba K, Saeki T, et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV study group of Japan. Int J Clin Oncol. 2015;20(5):855–865. doi: 10.1007/s10147-015-0786-7
   PubMed Web of Science ®Google Scholar
• Hata A, Okamoto I, Inui N, et al. Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol. 2022;40(2):180–188. doi: 10.1200/JCO.21.01315
   PubMed Web of Science ®Google Scholar
• Hata A, Shiraishi Y, Inui N, et al. Exploratory analysis comparing fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, phase 3 study (CONSOLE). Oncol Ther. 2022;10(1):253–262. doi: 10.1007/s40487-022-00188-2
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN clinical practice guidelines in oncology. Antiemetics, version 2. [Accessed 2023 May 4]. Available from https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
   Google Scholar
• Hesketh PJ. (2020) Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–2797. doi: 10.1200/JCO.20.01296
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Roila F, Warr D, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25(1):277–288. doi: 10.1007/s00520-016-3313-0
   PubMed Web of Science ®Google Scholar
• Aogi K, Takeuchi H, Saeki T, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan society of clinical oncology clinical practice guidelines for Antiemesis. Int J Clin Oncol. 2021;26(1):1–17. doi: 10.1007/s10147-020-01818-3
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the aprepitant protocol 052 study group. J Clin Oncol. 2003;21(22):4112–4119. Protocol 052. doi: 10.1200/JCO.2003.01.095
   PubMed Web of Science ®Google Scholar
• de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003;21(22):4105–4111. doi: 10.1200/JCO.2003.10.128
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12):3090–3098. doi: 10.1002/cncr.11433
   PubMed Web of Science ®Google Scholar
• Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97(9):2290–2300. doi: 10.1002/cncr.11320
   PubMed Web of Science ®Google Scholar
• Takahashi T, Hoshi E, Takagi M, et al. Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci. 2010;101(11):2455–2461. doi: 10.1111/j.1349-7006.2010.01689.x
   PubMed Web of Science ®Google Scholar
• Chow R, B YL, Baqri W, et al. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis. Support Care Cancer. 2023;31(8):505. doi: 10.1007/s00520-023-07978-y
   PubMed Web of Science ®Google Scholar
• Sun Y, Zheng Y, Yang X, et al. Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China. J Cancer Res Clin Oncol. 2021;147(9):2701–2708. doi: 10.1007/s00432-021-03554-1
   PubMed Web of Science ®Google Scholar
• Li Y, Sun Y, Liu B, et al. Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting. Future Oncol. 2022;18(20):2533–2543. doi: 10.2217/fon-2021-1523
   PubMed Web of Science ®Google Scholar
• Jordan K, Kinitz I, Voigt W, et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer. 2009;45(7):1184–1187. doi: 10.1016/j.ejca.2008.11.046
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J Clin Oncol. 2003;21(22):4112–4119. doi: 10.1200/jco.2003.01.095
   PubMed Web of Science ®Google Scholar
• Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncology. 2003;8(2):187–198. doi: 10.1634/theoncologist.8-2-187
   Google Scholar
• Aapro M, Carides A, Rapoport BL, et al. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncology. 2015;20(4):450–458. doi: 10.1634/theoncologist.2014-0229
   Google Scholar
• Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea, and vomiting: time for more emphasis on nausea? Oncology. 2015;20(6):576–583. doi: 10.1634/theoncologist.2014-0438
   Google Scholar
• Langford P, Chrisp P. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid. 2010;5:77–90. doi: 10.2147/ce.s6012
   PubMedGoogle Scholar
• Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol. 2011;29(11):1495–1501. doi: 10.1200/JCO.2010.31.7859
   PubMed Web of Science ®Google Scholar
• Ando Y, Hayashi T, Ito K, et al. Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy. Support Care Cancer. 2016;24(2):871–878. doi: 10.1007/s00520-015-2856-9
   PubMed Web of Science ®Google Scholar
• Aoki S, Iihara H, Nishigaki M, et al. Difference in the emetic control among highly emetogenic chemotherapy regimens: implementation for appropriate use of aprepitant. Mol Clin Oncol. 2013;1(1):41–46. doi: 10.3892/mco.2012.15
   PubMedGoogle Scholar